Bradley Jenna, O'Shea Patrick, Wrench Catherine, Mattsson Johan, Paulin Roxane, Overed-Sayer Catherine, Rosenberg Laura, Olsson Henric, Gianni Davide
Centre of Genomic Research, Discovery Sciences, BioPharmaceuticals R&D, Astrazeneca, Cambridge, United Kingdom.
Centre of Genomic Research, Discovery Sciences, BioPharmaceuticals R&D, Astrazeneca, Cambridge, United Kingdom.
SLAS Discov. 2025 Apr;32:100223. doi: 10.1016/j.slasd.2025.100223. Epub 2025 Feb 28.
Senescent cells contribute to the pathogenesis of idiopathic pulmonary fibrosis (IPF), a disease with significant unmet need and therefore, there is an interest in discovering new drug targets that regulate this process. We design and perform a phenotypic screen with a secreted protein library in primary human lung fibroblasts to identify modulators of cell senescence. We identify FGF9 as a suppressor of several senescence phenotypes reducing stimulated p21 expression, enlarged morphology, DNA damage and SASP secretion, which is consistent with both DNA-damage and ROS induced senescence. We also show that FGF9 reduces fibroblast activation in both healthy and IPF fibroblasts shown by a reduction in pro-fibrotic markers such as α-smooth muscle actin and COL1A1 mRNA. Our findings identify FGF9 as a suppressor of both senescence and fibrotic features in lung fibroblasts and therefore could be targeted as a new therapeutic strategy for respiratory diseases such as IPF.
衰老细胞在特发性肺纤维化(IPF)的发病机制中起作用,这是一种存在重大未满足需求的疾病,因此,人们对发现调节这一过程的新药物靶点很感兴趣。我们设计并使用原代人肺成纤维细胞中的分泌蛋白文库进行了表型筛选,以鉴定细胞衰老的调节剂。我们确定FGF9是几种衰老表型的抑制剂,可降低刺激后的p21表达、增大的形态、DNA损伤和衰老相关分泌表型(SASP)分泌,这与DNA损伤和ROS诱导的衰老均一致。我们还表明,FGF9可降低健康和IPF成纤维细胞中的成纤维细胞活化,这通过诸如α-平滑肌肌动蛋白和COL1A1 mRNA等促纤维化标志物的减少得以体现。我们的研究结果确定FGF9是肺成纤维细胞衰老和纤维化特征的抑制剂,因此可作为IPF等呼吸系统疾病的新治疗策略的靶点。